Cargando…
P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431347/ http://dx.doi.org/10.1097/01.HS9.0000847484.83317.ef |
| _version_ | 1784780029687758848 |
|---|---|
| author | Yazji, S. Hamburger, S. Wang, Y. Yavrom, S. Pietrofeso, A. Bliss, R. Breitmeyer, J. B. Dreyling, M. Wang, M. |
| author_facet | Yazji, S. Hamburger, S. Wang, Y. Yavrom, S. Pietrofeso, A. Bliss, R. Breitmeyer, J. B. Dreyling, M. Wang, M. |
| author_sort | Yazji, S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431347 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94313472022-08-31 P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA Yazji, S. Hamburger, S. Wang, Y. Yavrom, S. Pietrofeso, A. Bliss, R. Breitmeyer, J. B. Dreyling, M. Wang, M. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431347/ http://dx.doi.org/10.1097/01.HS9.0000847484.83317.ef Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Yazji, S. Hamburger, S. Wang, Y. Yavrom, S. Pietrofeso, A. Bliss, R. Breitmeyer, J. B. Dreyling, M. Wang, M. P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA |
| title | P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA |
| title_full | P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA |
| title_fullStr | P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA |
| title_full_unstemmed | P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA |
| title_short | P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA |
| title_sort | p1154: study zilo-301: a phase 3, randomized, double-blind, placebo-controlled, multicenter study of zilovertamab plus ibrutinib vs ibrutinib in patients with relapsed or refractory mantle cell lymphoma |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431347/ http://dx.doi.org/10.1097/01.HS9.0000847484.83317.ef |
| work_keys_str_mv | AT yazjis p1154studyzilo301aphase3randomizeddoubleblindplacebocontrolledmulticenterstudyofzilovertamabplusibrutinibvsibrutinibinpatientswithrelapsedorrefractorymantlecelllymphoma AT hamburgers p1154studyzilo301aphase3randomizeddoubleblindplacebocontrolledmulticenterstudyofzilovertamabplusibrutinibvsibrutinibinpatientswithrelapsedorrefractorymantlecelllymphoma AT wangy p1154studyzilo301aphase3randomizeddoubleblindplacebocontrolledmulticenterstudyofzilovertamabplusibrutinibvsibrutinibinpatientswithrelapsedorrefractorymantlecelllymphoma AT yavroms p1154studyzilo301aphase3randomizeddoubleblindplacebocontrolledmulticenterstudyofzilovertamabplusibrutinibvsibrutinibinpatientswithrelapsedorrefractorymantlecelllymphoma AT pietrofesoa p1154studyzilo301aphase3randomizeddoubleblindplacebocontrolledmulticenterstudyofzilovertamabplusibrutinibvsibrutinibinpatientswithrelapsedorrefractorymantlecelllymphoma AT blissr p1154studyzilo301aphase3randomizeddoubleblindplacebocontrolledmulticenterstudyofzilovertamabplusibrutinibvsibrutinibinpatientswithrelapsedorrefractorymantlecelllymphoma AT breitmeyerjb p1154studyzilo301aphase3randomizeddoubleblindplacebocontrolledmulticenterstudyofzilovertamabplusibrutinibvsibrutinibinpatientswithrelapsedorrefractorymantlecelllymphoma AT dreylingm p1154studyzilo301aphase3randomizeddoubleblindplacebocontrolledmulticenterstudyofzilovertamabplusibrutinibvsibrutinibinpatientswithrelapsedorrefractorymantlecelllymphoma AT wangm p1154studyzilo301aphase3randomizeddoubleblindplacebocontrolledmulticenterstudyofzilovertamabplusibrutinibvsibrutinibinpatientswithrelapsedorrefractorymantlecelllymphoma |